MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
Kim Dowling is a Senior Clinical Data Manager at Melanoma Institute Australia (MIA). Read on to learn about Kim's role, what she loves about her job, plus a few fun facts about her!
Researchers have reported results from an international clinical trial assessing alternative treatment options for lentigo maligna - a non-invasive condition that commonly occurs on sun-exposed areas, particularly the face.
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
